Margetuximab Approved for HER2+ Metastatic Breast Cancer ...Middle East

Medscape - News
A new monoclonal antibody targeting HER2 in breast cancer, margetuximab-cmkb, has shown superiority over trastuzumab in improving progression-free survival in heavily pretreated women. FDA Approvals

Hence then, the article about margetuximab approved for her2 metastatic breast cancer was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Margetuximab Approved for HER2+ Metastatic Breast Cancer )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News